Tear Protein Microbial Regulation

泪液蛋白微生物调节

基本信息

  • 批准号:
    10398176
  • 负责人:
  • 金额:
    $ 45.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-30 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Tear microbicidal activity protects the surface of the eye from environmental pathogens and may regulate levels of commensal bacteria. Lacritin, a prosecretory mitogen enriched in human basal and reflex tears, is subject to cleavage-potentiated release of C-terminal proteoforms, including those bactericidal for E. coli, P. aeruginosa (Migula and PA14), L. monoctyogenes, S. aureus and S. epidermidis. Removal of C-terminal proteoforms from human tears by repeated passage over anti-lacritin C- (but not N-) terminal antibody columns depletes all tear antimicrobial activity, an activity encapsulated in the synthetic peptide AQKLLKKFSLLKPWA 'N-104', also a proteoform. As a cationic, largely a-helical amphipathic peptide, death by membrane disruption would be expected - a hypothesis largely ruled out by surface plasmon resonance with model bacterial membranes, and metabolomic analysis with parent 'N-65' fragment that suggests a regulated cell death mechanism. Very revealing were screens for N-104 resistant mutants out of the full E. coli Keio collection of 3,985 nonessential gene knockouts. Knockout of feoB, potH, ybaE, yhfZ or ybdM was sufficient to confer resistance, but not to equimolar amounts of ampicillin. The same is true for feoB and potH transposon insertion mutants of opportunistic pathogen P. aeruginosa PA14. YbaE and YbdM are uncharacterized in E. coli and P. aeruginosa where functions may differ. YhfZ is absent from P. aeruginosa. FeoB is a well-known virulence factor of respiratory P. aeruginosa, F. tularensis and L. pneumophila, gut C. jejuni and H. pylori, and uropathogenic E. coli, but has not previously been associated with ocular infections. FeoB and PotH contribute to or form respective ferrous iron and putrescine and uptake channels, YbaE (with proposed name 'bacterial extracellular solute-binding protein') appears to be an ABC transporter subunit with a genetic interaction to outer membrane protein A, and YbdM is a ParB domain containing nuclease. Ferrous iron and putrescine are each essential for bacterial cell growth, and yet are also required by host cells, especially the avascular cornea. Media supplementation with a 10-fold molar excess of putrescine, but not fellow polyamine spermidine, completely abrogates N-104 dependent bacterial death (tear putrescine is 1/10th that of N-104 proteoform). Complementation of potH- E. coli by potH+ cDNA does the opposite. Prior metabolomic studies (that did not detect ferrous iron) revealed that N-104 parent 'N-65' rapidly suppresses intracellular E. coli putrescine. Our immediate focus is on FeoB and PotH. Our working hypothesis is that FeoB and/or PotH are virulence mechanisms for ocular surface pathogens with N-104 a main source of tear bactericidal activity. Our immediate goal is to elucidate how N-104, through FeoB or PotH triggers killing. University of Virginia Charlottesville Virginia Harvard University Boston Massachusetts
泪液杀菌活性可保护眼睛表面免受环境病原体的侵害,并可调节水平 共生细菌。泪素是一种富含人类基础泪液和反射泪液的促分泌性有丝分裂原, C 末端蛋白质形式的裂解增强释放,包括对大肠杆菌、铜绿假单胞菌具有杀菌作用的蛋白质形式 (Migula 和 PA14)、单核乳杆菌、金黄色葡萄球菌和表皮葡萄球菌。去除 C 末端蛋白形式 通过反复通过抗乳泌素 C-(而非 N-)末端抗体柱,人类泪液会耗尽所有泪液 抗菌活性,一种封装在合成肽 AQKLLKKFSLLKPWA“N-104”中的活性,也是一种 蛋白质型。作为一种阳离子、大部分为α螺旋的两亲肽,膜破坏导致的死亡将是 预期 - 这一假设很大程度上被模型细菌膜的表面等离振子共振所排除,并且 使用母体“N-65”片段进行的代谢组学分析表明存在受调节的细胞死亡机制。非常 从包含 3,985 个非必需品的完整大肠杆菌 Keio 集合中筛选出 N-104 抗性突变体,结果揭示了这一点 基因敲除。 feoB、potH、ybaE、yhfZ 或 ybdM 的敲除足以赋予抗性,但不足以赋予抗性 等摩尔量的氨苄西林。 feoB 和 potH 转座子插入突变体也是如此 机会致病菌铜绿假单胞菌 PA14。 YbaE 和 YbdM 在大肠杆菌和铜绿假单胞菌中没有特征 其中功能可能有所不同。铜绿假单胞菌中不存在 YhfZ。 FeoB 是众所周知的毒力因子 呼吸道铜绿假单胞菌、土拉杆菌和嗜肺军团菌、肠道空肠弯曲菌和幽门螺杆菌,以及泌尿道致病性大肠杆菌。 大肠杆菌,但之前并未发现与眼部感染有关。 FeoB 和 PotH 有助于或形成 各自的二价铁和腐胺以及摄取通道,YbaE(建议名称“细菌细胞外 溶质结合蛋白')似乎是与外膜具有遗传相互作用的 ABC 转运蛋白亚基 蛋白 A,YbdM 是包含核酸酶的 ParB 结构域。二价铁和腐胺对于 细菌细胞生长,但也是宿主细胞,特别是无血管角膜所必需的。媒体 完全补充 10 倍摩尔过量的腐胺,但不完全补充聚胺亚精胺 消除 N-104 依赖性细菌死亡(泪液腐胺是 N-104 蛋白质形式的 1/10)。 potH+ cDNA 对 potH- 大肠杆菌的补充则起到相反的作用。先前的代谢组学研究(没有 检测二价铁)表明 N-104 母体“N-65”可快速抑制细胞内大肠杆菌腐胺。我们的 目前的焦点是 FeoB 和 PotH。我们的工作假设是 FeoB 和/或 PotH 具有毒力 N-104 是泪液杀菌活性的主要来源,对眼表病原体的作用机制。我们的即时 目标是阐明 N-104 如何通过 FeoB 或 PotH 触发杀伤。 弗吉尼亚大学弗吉尼亚州夏洛茨维尔分校 哈佛大学 马萨诸塞州波士顿分校

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gordon William Laurie其他文献

Gordon William Laurie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gordon William Laurie', 18)}}的其他基金

Tear Protein Microbial Regulation
泪液蛋白微生物调节
  • 批准号:
    10615707
  • 财政年份:
    2016
  • 资助金额:
    $ 45.81万
  • 项目类别:
Tear Protein Microbial Regulation
泪液蛋白微生物调节
  • 批准号:
    9010167
  • 财政年份:
    2016
  • 资助金额:
    $ 45.81万
  • 项目类别:
Tear Protein Microbial Regulation
泪液蛋白微生物调节
  • 批准号:
    10211706
  • 财政年份:
    2016
  • 资助金额:
    $ 45.81万
  • 项目类别:
Lacritin Regulated Ocular Surface Homeostasis
泪泌素调节眼表稳态
  • 批准号:
    9060945
  • 财政年份:
    2014
  • 资助金额:
    $ 45.81万
  • 项目类别:
Lacritin Regulated Ocular Surface Homeostasis
泪泌素调节眼表稳态
  • 批准号:
    8672811
  • 财政年份:
    2014
  • 资助金额:
    $ 45.81万
  • 项目类别:
BIOTECHNOLOGY TRAINING PROGRAM
生物技术培训计划
  • 批准号:
    7914825
  • 财政年份:
    2009
  • 资助金额:
    $ 45.81万
  • 项目类别:
Modeling Novel Treatments for Dry Eye
干眼症新疗法建模
  • 批准号:
    7502589
  • 财政年份:
    2007
  • 资助金额:
    $ 45.81万
  • 项目类别:
Modeling Novel Treatments for Dry Eye
干眼症新疗法建模
  • 批准号:
    8128497
  • 财政年份:
    2007
  • 资助金额:
    $ 45.81万
  • 项目类别:
Modeling Novel Treatments for Dry Eye
干眼症新疗法建模
  • 批准号:
    7250497
  • 财政年份:
    2007
  • 资助金额:
    $ 45.81万
  • 项目类别:
Modeling Novel Treatments for Dry Eye
干眼症新疗法建模
  • 批准号:
    7908759
  • 财政年份:
    2007
  • 资助金额:
    $ 45.81万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 45.81万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 45.81万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 45.81万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 45.81万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了